John Richard Pinion - 06 May 2021 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP of Translational Sciences and Chief Quality Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
06 May 2021
Net transactions value
-$41,269
Form type
4
Filing time
10 May 2021, 18:13:14 UTC
Next filing
18 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $41,269 -363 -0.72% $113.69 50,122 06 May 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F2 Includes 248 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2021.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Remarks:

EVP of Translational Sciences and Chief Quality Officer